Le CRPP est un réseau d'experts universitaires en politique pharmaceutique. Nous collaborons en vue d’élaborer et de promouvoir des recherches sur les questions qui importent aux canadiens.

Recherche recommandée

“To patent or not to patent? the case of Novartis’ cancer drug Glivec in India”

This paper provides an analysis of the legal battles surrounding the patentability of Glivec in India. The authors argue that this case sets an important precedent for the global pharmaceutical industry and ideally will help improve access to drugs in the developing world by demanding that patient health needs supersede commercial interests.

Economics and industry do not mean ethical conduct in clinical trials

This article examines the ethical dilemma clinical trials present for pharmaceutical companies. Nine examples of how clinical trials are violating multiple articles in the Declaration of Helsinki are discussed using concrete case reports from the literature.

, 2013

Health Canada and the Pharmaceutical Industry: A Preliminary Analysis of the Historical Relationship

This paper provides a preliminary examination of the history of the relationship between Health Canada and attempts to discern whether the introduction of user fees by the industry in 1994 represented a key turning point. Clientele pluralism, a theory that explains the relationship between the state and interest groups, is used to explain the nature of the events described.

Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers

This article documents policy considerations related to the use of reimbursement contracts that include confidential price term in Canada. Motivations for and challenges associated with use are explored.

Private Expenditures on Brand Name Prescription Drugs after Generic Entry

This study investigates excess spending by private drug plans in Canada resulting from expenditures on brand name drugs after generics become available. New policies to combat such financial inefficiencies are discussed.

, 2013
1
2
3
4
5